ERBB2 and neoplasm: TRA can prevent HER2 hetero-dimerization and stop tumor development cell signaling via several mechanisms, including reduced PI3K/Akt signaling, enhanced degradation of HER2 receptors, and antibody-dependent cellular cytotoxicity (ADCC).